Recent development of single preparations and fixed-dose combination tablets for the treatment of non-insulin-dependent diabetes mellitus
Archives of Pharmacal Research 2016³â 39±Ç 6È£ p.731 ~ p.746
(Li Jianwen) - Shenyang Pharmaceutical University School of Pharmacy
(Lian He) - Shenyang Pharmaceutical University School of Pharmacy
Abstract
As a complex endocrine and metabolic disorder, type 2 diabetes mellitus (non-insulin-dependent diabetes mellitus, NIDDM) has become a major threat to human health. Because of the heterogeneous and progressive disorders induced by insulin resistance and pancreatic b-cell dysfunction, the treatment of NIDDM is still challenging. Although antidiabetic drugs with different pharmacological mechanisms of action have been used clinically, different degrees of undesirable glucose control and the incidences of a variety of side effects, including hypoglycemia, cardiovascular complications and weight gain require the better treatment options. This article has overviewed the current literature about commercially available antidiabetic drugs with different pharmacological mechanisms of action in the treatment of NIDDM, and summarized the published data regarding the efficacy, tolerability, and safety of currently available single preparations and fixed-dose combinations, aiming to provide important information for the development and application of antidiabetic drugs in the future. The literature search from 1989 to 2015 was conducted by PubMed, ScienceDirect, Springer, American Diabetes Association, and U.S. FDA Drugs databases.
Å°¿öµå
Non-insulin-dependent diabetes mellitus, NIDDM, Drug efficiency and safety, Medical treatment, Single preparations, Fixed-dose combination tablets, FDCs
KMID :
0043320160390060731
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
The strategy of fixed-dose combinations can simplify complicated treatment regimens with many advantages as following: (1) greater efficacy of glucose control; (2) prevention the occurrence of side effect and cardiovascular complications; (3) reduced costs; (4) drug compliance increment.